Grants / Department of Health and Human Services / National Institutes of Health

RFA-MH-22-111: Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Assay and Data Generation Centers (RM1 Clinical Trial Not Allowed)

Closed Closed June 10, 2022 Opportunity RFA-MH-22-111 ☆ Save

This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.

• Award amountsNot given on Grants.gov
• Cost sharingNot required
• Funding typeGrant

Key dates

Who can apply

This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses.

Is this a realistic fit?

• Most of the program's money (69% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

This funding opportunity announcement (FOA) supports systematic and scalable approaches to profile the biological function of genes with an excess of damaging mutations in patients with neurodevelopmental and psychiatric disorders. Current understanding of the relationship between genetic and phenotypic variation is limited and one of the main bottlenecks in translating disease-associated genes to biology lies in the lack of scalable experimental platforms that can extend the unbiased nature of gene discovery to the discovery of biological mechanisms. This concept will attempt to fill that gap while also providing a bridge between existing NIMH efforts such as PsychENCODE and Convergent Neuroscience. New technologies and approaches are now making it possible to systematically implement high-throughput assays to determine how disease-linked genetic variation impacts neural function across biological levels of organization. This initiative proposes a series of FOAs to support the large-scale implementation of high-throughput assays to interrogate the molecular, cellular and physiological function of hundreds of disease-associated genes in parallel. A combination of full-scale and pilot projects will form a consortium for broad characterization of risk genes across an array of endpoints relevant to CNS function using a variety of experimental platforms (e.g., cellular, organismal). A consortium coordination center (CCC) will serve as a central hub providing administrative coordination across projects, including data and tools harmonization, development of an open-source portal to create a unified dataset and creating a standardized set of biological resources for use by the research community.

Category: Health.

Applying now

This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.